Evidence map›Paper›PMID 39013999›Full record

ArticleScientific reports2024

The association of breast cancer patients survival and prior menopausal hormone therapy in women with type 2 diabetes.

Mayu Hosio, Elina Urpilainen, Ari Hautakoski, Martti Arffman, Reijo Sund, Anne Ahtikoski, Ulla Puistola, Arja Jukkola, Esa Läärä, Peeter Karihtala

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mayu HosioDepartment of Oncology and Radiotherapy, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, University of Oulu, Oulu, Finland.
Elina UrpilainenMedical Research Center, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, University of Oulu, Oulu, Finland.
Ari HautakoskiMedical Research Center, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, University of Oulu, Oulu, Finland.
Martti ArffmanDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Reijo SundInstitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Anne AhtikoskiFimlab Laboratories, Department of Pathology, University of Tampere, Tampere, Finland.
Ulla PuistolaMedical Research Center, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, University of Oulu, Oulu, Finland.
Arja JukkolaDepartment of Oncology and Radiotherapy, Tays Cancer Center, Tampere University Hospital, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Esa LääräResearch Unit of Mathematical Sciences, University of Oulu, Oulu, Finland.
Peeter KarihtalaDepartment of Oncology and Radiotherapy, Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, University of Oulu, Oulu, Finland. peeter.karihtala@hus.fi.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the association of prediagnostic use of menopausal hormone therapy (MHT) with breast cancer survival among women with type 2 diabetes (T2D). The study cohort was identified from a Finnish nationwide diabetes database, and consisted of women with T2D, who were diagnosed with breast cancer between 2000 and 2011 (n = 3189). The patients were classified according to their previous MHT use: systemic MHT, local MHT, and no history of any MHT. The cumulative mortality from breast cancer, cardiovascular diseases, and other causes in three MHT groups was described by the Aalen-Johansen estimator. The cause-specific mortality rates were analyzed by Cox models, and adjusted hazard ratios (HRs) were estimated for the use of MHT. The breast cancer mortality appeared to be lower among systemic MHT users (HR 0.49, 95% Cl 0.36-0.67) compared with non-users of MHT. The mortality from cardiovascular diseases and from other causes of death was found to be lower among systemic MHT users, (HR 0.49, 95% Cl 0.32-0.74), and (HR 0.51, 95% Cl 0.35-0.76), respectively. In conclusion, prediagnostic systemic MHT use is associated with reduced breast cancer, cardiovascular, and other causes of mortality in women with T2D.

Indexed as

Breast NeoplasmsDiabetes Mellitus, Type 2AgedCardiovascular DiseasesFemaleFinlandHormone Replacement TherapyHumansMenopauseMiddle AgedProportional Hazards Models

Identifiers

PMID39013999
PMCPMC11252321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.